Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)114
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-1981
Patented therapeutic drug delivery strategies for targeting pulmonary diseases62
An updated patent review of p38 MAP kinase inhibitors (2014-2019)51
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature50
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review46
Repurposing drugs for the management of COVID-1944
Antimicrobial peptides (AMPs): a patent review (2015–2020)43
Sirtuin modulators: where are we now? A review of patents from 2015 to 201937
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)37
Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020)34
Biofilm and Quorum Sensing inhibitors: the road so far34
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)33
Antibiotic resistance and bacterial biofilm32
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present31
Natural compounds and extracts as novel antimicrobial agents31
Microneedles as an alternative technology for transdermal drug delivery systems: a patent review31
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents30
Inhibitory activities of indolizine derivatives: a patent review30
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)29
The therapeutic potential of PROTACs29
A deadly spillover: SARS-CoV-2 outbreak28
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)27
An updated patent review of VEGFR-2 inhibitors (2017-present)27
Synthetic molecules as DprE1 inhibitors: A patent review27
An updated patent review of anticancer Hsp90 inhibitors (2013-present)27
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)26
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)26
Neurokinin receptor antagonism: a patent review (2014-present)25
Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015–2019)25
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019)23
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)22
Soluble guanylate cyclase stimulators and their potential use: a patent review22
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)22
Protease inhibitors targeting the main protease and papain-like protease of coronaviruses22
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature20
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)20
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)20
TRPV4 antagonists: a patent review (2015–2020)20
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)20
Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–201919
Steroid sulfatase inhibitors: the current landscape19
A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019)19
Factor XII(a) inhibitors: a review of the patent literature19
A patent review of topoisomerase I inhibitors (2016–present)19
Antiviral therapeutics for chikungunya virus19
Ligands for cereblon: 2017–2021 patent overview19
A 2018–2019 patent review of metallo beta-lactamase inhibitors18
Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 202018
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective18
Thioredoxin reductase inhibitors: updated patent review (2017-present)18
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)18
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates18
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)18
GPR120 agonists for the treatment of diabetes: a patent review (2014 present)17
Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature17
Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-202217
An updated patent review of autotaxin inhibitors (2017–present)16
A patent review of transient receptor potential vanilloid type 1 modulators (2014–present)16
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)16
Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)16
Anti-viral activity of thiazole derivatives: an updated patent review15
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade15
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)15
Recent updates on Wnt signaling modulators: a patent review (2014-2020)15
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)15
Therapeutic approaches targeting the neurotensin receptors15
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)15
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 202114
A patent review of berberine and its derivatives with various pharmacological activities (2016–2020)14
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents14
An updated patent review on drugs for the treatment of tuberculosis (2018-present)14
A patent review of MALT1 inhibitors (2013-present)14
Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 202114
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature14
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)13
Tankyrase inhibitors as antitumor agents: a patent update (2013 – 2020)13
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)13
Mucormycosis medications: a patent review13
Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents13
Potential of microRNA based diagnostics and therapeutics in glioma: a patent review13
Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)13
An update on the therapeutic potential of calpain inhibitors: a patent review13
An overview of ghrelinO-acyltransferase inhibitors: a literature and patent review for 2010-201913
Inhibitors of RIP1 kinase: a patent review (2016–present)12
Patent landscape of pediatric-friendly oral dosage forms and administration devices12
Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)12
N-heterocyclic carbene metal complexes as therapeutic agents: a patent review12
JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)11
Phosphoglycerate dehydrogenase (PHGDH) inhibitors: a comprehensive review 2015–202011
An updated patent review on monoamine oxidase (MAO) inhibitors11
Searching for effective antiviral small molecules against influenza A virus: A patent review11
Aurora kinase inhibitors: a patent review (2014-2020)11
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)11
Phosphodiesterase‑4 inhibitors: a review of current developments (2013–2021)10
The patent maze of COVID 19 vaccines10
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)10
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)10
Tackling prion diseases: a review of the patent landscape10
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)10
Metal organic frameworks (MOFs) with therapeutic and biomedical applications: a patent review10
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)10
TGR5 agonists for diabetes treatment: a patent review and clinical advancements (2012-present)9
Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015–2020)9
Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property9
Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents8
Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US20183260548
An updated patent review of Akt inhibitors (2016-present)8
OX40 agonists for cancer treatment: a patent review8
An updated patent review of glutaminase inhibitors (2019–2022)8
A patent review of mTOR inhibitors for cancer therapy (2011–2020)8
Challenges in the development of next-generation antibiotics: opportunities of small molecules mimicking mode of action of host-defense peptides8
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)8
Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review8
Repositioning and investigational drugs for Zika virus infection treatment: a patent review8
GABAA receptor subtype modulators in medicinal chemistry: an updated patent review (2014-present)8
GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)7
Coronaviruses7
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present)7
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present7
Current status and patent prospective of lipid nanoparticle for mRNA delivery7
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)7
Inhibitory activities of bipyrazoles: a patent review7
Monocyclic beta–lactams for therapeutic uses: a patent overview (2010–2020)7
An updated patent review of Nrf2 activators (2020-present)7
BET inhibitors: an updated patent review (2018–2021)7
0.036479949951172